Evidence map›Paper›PMID 32803833›Full record

ArticleDrug testing and analysis2020

Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ).

Simon D Brandt, Pierce V Kavanagh, Folker Westphal, Alexander Stratford, Simon P Elliott, Geraldine Dowling, Adam L Halberstadt

Open access · hybridAbstract read
In one paragraph

Article in Drug testing and analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Frontiers in psychiatry · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 5 countries.

Simon D BrandtSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.ORCID https://orcid.org/0000-0001-8632-5372
Pierce V KavanaghDepartment of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St James Hospital, Dublin, Ireland.ORCID https://orcid.org/0000-0002-1613-3305
Folker WestphalState Bureau of Criminal Investigation Schleswig-Holstein, Section Narcotics/Toxicology, Kiel, Germany.ORCID https://orcid.org/0000-0003-0452-7814
Alexander StratfordSynex Synthetics BV, Maastricht, The Netherlands.
Simon P ElliottElliott Forensic Consulting, Birmingham, UK.ORCID https://orcid.org/0000-0001-5219-1687
Geraldine DowlingDepartment of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St James Hospital, Dublin, Ireland.ORCID https://orcid.org/0000-0001-8344-6582
Adam L HalberstadtDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.ORCID https://orcid.org/0000-0001-5096-5829
Trinity College Dublin · IEClinical Research Center Kiel · DELiverpool John Moores University · GBSynapse (Netherlands) · NLUniversity of California San Diego · US

Funding

The Next Generation of Hallucinogens: A New Class of Synthetic Psychoactive DrugsR01DA041336 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HALBERSTADT, ADAM L. · 2017 to 2020
$1.4M
NIDA NIH HHS R01 DA041336
6 · The paper itself

Abstract

Recent investigations have shown that N-ethyl-N-cyclopropyl lysergamide (ECPLA) produces LSD-like behavioral effects in mice, which suggests that it may act as a hallucinogen in humans. Although the use of ECPLA as a recreational drug has been limited, key analytical data that can be used to detect ECPLA are required for future forensic and clinical investigations. ECPLA is an isomer of (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ), a lysergamide that emerged as a recreational drug in 2013. Several analytical approaches were examined, including single- and tandem mass spectrometry platforms at low and high resolution, gas- and liquid chromatography (GC, LC), nuclear magnetic resonance spectroscopy (NMR), and GC condensed-phase infrared spectroscopy (GC-sIR). ECPLA and LSZ could be differentiated by NMR, GC-sIR, GC, and LC-based methods. The electron ionization mass spectra of ECPLA and LSZ contained ion clusters typically observed with related lysergamides such as m/z 150-155, m/z 177-182, m/z 191-197, m/z 205-208, and m/z 219-224. One of the significant differences in abundance related to these clusters included ions at m/z 196 and m/z 207/208. The base peaks were detected at m/z 221 in both cases followed by the retro-Diels-Alder fragment at m/z 292. Minor but noticeable differences between the two isomers could also be seen in the relative abundance of m/z 98 and m/z 41. Electrospray ionization mass spectra included lysergamide-related ions at m/z 281, 251, 223, 208, 197, 180, and 140. LSZ (but not ECPLA) showed product ions at m/z 267 and m/z 98 under the conditions used.

Indexed as

Chromatography, High Pressure LiquidGas Chromatography-Mass SpectrometryIllicit DrugsIsomerismLysergic AcidMagnetic Resonance SpectroscopySpectrometry, Mass, Electrospray IonizationTandem Mass SpectrometryIllicit DrugsLysergic Acidforensic, isomersLSDnew psychoactive substancespsychedelics

Identifiers

PMID32803833
PMCPMC9191644
OpenAlexW3049359011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.